Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma.

ABSTRACT:

Background

The presence of bone metastases in renal cell carcinoma (RCC) negatively affects patients' survival. Data from clinical trials has highlighted a significant benefit of cabozantinib in bone metastatic RCC patients. Here, we evaluated the antitumor effect of cabozantinib in coculture models of renal cell carcinoma (RCC) and osteoblasts (OBs) to investigate whether and how its antiproliferative activity is influenced by OBs.

Methods

Bone/RCC models were generated, coculturing green fluorescent protein (GFP)-tagged Caki-1 and 786-O cells with human primary OBs in a "cell-cell contact" system. RCC proliferation and the OB molecular profile were evaluated after the cabozantinib treatment.

Results

The Caki-1 cell proliferation increased in the presence of OBs (

SUBMITTER: Iuliani M 

PROVIDER: S-EPMC8389553 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature